Phreesia, Inc.

Phreesia, Inc. (PHR) Market Cap

Phreesia, Inc. has a market capitalization of $589.7M.

Price: $9.54

-0.15 (-1.55%)

Market Cap: 589.69M

NYSE · time unavailable

CEO: Chaim Indig

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2019-07-18

Website: https://www.phreesia.com

Phreesia, Inc. (PHR) - Company Information

Market Cap: 589.69M|Sector: Healthcare

Company Profile

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.

Analyst Sentiment

83%
Strong Buy

From 20 Active Polls

1Y Forecast: $15.00

▲ +57.2% Potential Upside

Consensus Target Metrics

Low Bound

$9

Median

$13

High Bound

$25

Average

$15

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$15.00
▲ +57.23% Upside
Low Target
$9.00
-6% Risk
Median Target
$13.00
36% Mid
High Target
$25.00
162% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

PHR Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$9.54
Intrinsic Value$9.53
Market Alignment
Overvalued by 0.1%relative to calculated intrinsic value
9.00%
Exp: 7%7%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2036)

Terminal FCF Base$0.14B
Perpetuity TV Value$2.64B
Discounted TV (PV)$1.02B
TV Weighting %60.3%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PHREESIA INC (PHR) — Investment Overview

🧩 Business Model Overview

Phreesia provides “digital front door” software used by healthcare providers to automate patient intake and pre-visit workflows. The value chain typically runs as: (1) configure patient-facing digital forms and intake workflows, (2) integrate intake data with provider systems used for clinical and administrative operations, and (3) route completed information into downstream processes that affect scheduling, registration, and billing readiness.

Deployment is oriented around embedding into established patient check-in and visit preparation workflows, creating operational stickiness once intake processes and system connections are in place.

💰 Revenue Streams & Monetisation Model

The monetisation model is primarily subscription-based, often structured around per-provider or per-location access and usage tiers, with revenue tied to active deployments rather than one-time software licenses. A portion of economics can also depend on add-on services or implementation/support activities associated with onboarding and workflow configuration.

Margin drivers are concentrated in software gross margin (low incremental cost per incremental patient interaction), scale benefits from centralized product development, and operating leverage from the sales/implementation motion once a provider network is established. Retention and expansion are key because switching away from integrated intake workflows is operationally disruptive.

🧠 Competitive Advantages & Market Positioning

Core moat: High Switching Costs (workflow and integration “data gravity”). Phreesia’s product is embedded in patient intake operations and connected to provider systems. That integration work—and the resulting downstream process changes (registration accuracy, reduced manual rework, and improved administrative throughput)—creates practical switching costs for providers. Competitors can offer overlapping front-end experiences, but displacing an operationally integrated intake workflow typically requires re-implementation, validation, and re-training across teams.

Competitive benchmarking (examples):

  • RevSpring: focuses on patient financial engagement and digital tools tied to payment readiness; overlaps in patient-facing automation but competes more on financial workflows than on end-to-end intake data capture.
  • ModMed: targets digital patient intake and engagement within provider operations; overlaps directly in intake automation where both platforms can be evaluated as “digital front door” solutions.
  • athenahealth / EHR-centric ecosystems: offer intake and workflow capabilities bundled or complemented by platform services; the advantage typically rests on broader system breadth, while Phreesia differentiates through specialized intake automation and deployment into existing workflows.

Positioning versus rivals: Phreesia’s industry focus is intake workflow automation at the patient’s point of interaction with the provider. EHR-centric competitors can bundle similar capabilities, but they face trade-offs in deploying specialized workflows across diverse operational environments. Financial engagement players may provide adjacent functionality but may not fully substitute for intake automation embedded in front-end visit preparation.

🚀 Multi-Year Growth Drivers

Growth over a 5–10 year horizon is supported by structural demand for administrative automation and improved patient experience without proportional increases in labor. Key drivers include:

  • Expansion of outpatient and multi-site delivery models: more locations and front-desk volume increases the economic case for standardized intake workflows.
  • Digitization of front-office processes: providers face pressure to reduce manual registration work, improve data completeness, and streamline visit readiness.
  • Data integration and workflow standardization: as providers modernize systems and seek interoperability, specialized intake tools can scale through repeatable implementations.
  • Operational efficiency incentives: administrative cost control and capacity management elevate ROI for automation solutions that improve throughput and reduce errors requiring manual correction.
  • Broader “digital patient journey” adoption: intake automation acts as a platform entry point that can support incremental workflow enhancements within the visit lifecycle.

TAM expansion is driven less by a one-time technology refresh and more by ongoing provider network modernization—where embedded workflow solutions can sell and expand across geographies, specialties, and facility types.

⚠ Risk Factors to Monitor

  • Integration and interoperability risk: product value depends on reliable connectivity to provider systems and workflows. Integration complexity or failures can increase churn risk or slow sales cycles.
  • Cybersecurity and privacy exposure: patient intake data is sensitive; breaches or compliance lapses can damage trust and lead to contract termination or regulatory scrutiny.
  • Buyer budget and utilization risk: provider demand can fluctuate with payer mix, reimbursement pressure, and administrative budget constraints, impacting procurement timing and renewal economics.
  • Competitive substitution: large platform providers may expand native intake features, and point-solution vendors may compete on price or packaging, compressing margins unless differentiation remains strong.
  • Implementation execution: onboarding quality affects retention. Poor configuration, workflow mismatch, or training gaps can reduce operational benefits and lead to underutilization.

📊 Valuation & Market View

Healthcare software companies with subscription revenue are typically valued on a combination of EV/Revenue (or EV/ARR), growth rate, and profitability trajectory rather than near-term earnings. Market focus tends to center on:

  • Recurring revenue quality: retention and expansion dynamics (net revenue retention), indicating the strength of switching costs and embedded workflows.
  • Unit economics: gross margin stability and operating leverage as sales and onboarding scale.
  • Sales efficiency: customer acquisition costs relative to lifetime value, influenced by deployment success and time-to-value.
  • Durability of demand: sustained provider digitization and administrative automation spending.

In this sector, valuation multiples expand when growth accelerates and retention remains resilient, and contract when implementation risk rises or churn increases—particularly if providers treat these tools as replaceable commodity software.

🔍 Investment Takeaway

Phreesia’s long-term thesis rests on operating workflow adoption—where integrated patient intake processes create practical switching costs. With healthcare providers continuing to digitize front-office operations and reduce administrative friction, Phreesia is positioned to benefit from recurring deployments and expansion within multi-location delivery networks, provided integration quality, security, and customer outcomes remain consistent.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-04-30

"PHR reported Q1’27 (ended 2026-04-30) revenue of $130.9M and net income of $6.5M (EPS $0.05), versus a much weaker prior quarter (Q4’26) with net income of $1.3M. QoQ revenue rose 3.1% (from $127.1M), and net income surged 401% (from $1.3M). On a YoY basis, revenue grew 12.8% (from $115.9M) and net income improved versus the prior-year loss of $(3.9)M to a profit of $6.5M—turning the bottom line materially. Profitability improved meaningfully: net margin expanded to 4.95% from 1.02% QoQ and from -3.38% YoY. The gross margin also strengthened (Q1’27 gross margin 86.5% vs 43.0% in Q4’26), while operating income and operating margin moved back to positive (operating margin 5.15% vs 2.89% QoQ and -2.84% YoY). Cash flow quality improved despite volatility in investing/financing: operating cash flow was $23.9M and free cash flow $19.6M in the quarter. Balance sheet resilience remains mixed but improving—cash is $74.7M and total equity is $359.1M, up from $337.2M QoQ, while long-term debt of $86.2M increased versus Q4’26. Shareholder returns appear pressured: the stock is down 61.6% over 1 year (momentum negative), with no dividend and no buybacks reported in the provided cash flow."

Revenue Growth

Positive

Revenue increased QoQ by 3.1% ($127.1M to $130.9M) and grew YoY by 12.8% ($115.9M to $130.9M), indicating an improving top-line trend.

Profitability

Positive

Net income improved sharply QoQ (+401%) and flipped YoY from -$3.9M to +$6.5M. Net margin expanded to 4.95% from 1.02% QoQ and from -3.38% YoY; operating margin also turned clearly positive.

Cash Flow Quality

Fair

Operating cash flow was $23.9M and free cash flow $19.6M in Q1’27, supporting the earnings rebound. However, financing/investing flows have been volatile across quarters and dividends/buybacks are not evident.

Leverage & Balance Sheet

Caution

Equity increased to $359.1M QoQ, but long-term debt rose to $86.2M. Liquidity is decent with cash of $74.7M, yet net debt remains modestly positive ($11.5M).

Shareholder Returns

Neutral

Total shareholder returns are weak: price is down 61.6% over 1 year. No dividends were paid in the quarter, and no buybacks are shown in the provided cash flow.

Analyst Sentiment & Valuation

Fair

Valuation multiples are elevated (e.g., price-to-sales ~4.29 in the supplied ratios) and the stock trades far below 1-year momentum. The consensus price target (~$21.86) implies upside vs the current price ($9.17), but the 1-year drawdown lowers confidence.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

PHR delivered an in-line Q1 FY27 profile with strong Payments momentum and improving profitability. Revenue was $130.9M (+13% YoY) led by 40% Payment Solutions growth, with Network Solutions up 15%. Adjusted EBITDA rose to $30.5M and margins ran at 23%, while net income swung to $3.0M from a net loss in the prior year. The quarter also introduced new payments KPIs (total managed payments $1.786B; Payment Solutions revenue rate 2.3%), clarifying how Access One’s managed portfolio is flowing into monetization. Guidance is unchanged: FY27 revenue $510M-$520M and adjusted EBITDA $125M-$135M, supported by ~$37M Access One contribution and continued mid-/low-single-digit AHSC and revenue-per-AHSC growth. The main macro/forecast risk is Network Solutions variability in 2H driven by client spend pacing and regulatory/brand-specific dynamics. Access One’s PNC securitization expansion (facility cap to $300M; through April 2029) meaningfully increases funding capacity and addressable reach, likely supporting retention and payments-driven economics even as subscription pricing is deliberately moderated.

AI IconGrowth Catalysts

  • Payment Solutions revenue growth +40% YoY driven by Access One (no prior-year contribution because acquisition closed in Q4 FY26)
  • Network Solutions revenue growth +15% YoY supported by momentum from newly launched Provider Connect product
  • Total managed payments platform scaling to $1.786B in Q1 with Payment Solutions revenue rate at 2.3%

Business Development

  • Access One securitization facility expanded with PNC Bank: facility limit increased from $200M to $300M; term extended through April 2029
  • Expanded Access One ability to offer upfront funding to non-investment-grade providers (addressable market expansion referenced alongside PNC amendment)

AI IconFinancial Highlights

  • Revenue $130.9M, +13% YoY; results described as in-line with expectations
  • Adjusted EBITDA $30.5M vs $20.8M prior year; adjusted EBITDA margin 23% (improved from prior-year 20.8M implied margin level but no explicit bps stated)
  • Net income $3.0M vs net loss $(3.9)M prior year; third consecutive quarter of positive net income
  • Average Healthcare Services Clients (AHSC) 4,700: +50 QoQ and +7% YoY (increase from 4,297 to 4,700 implied by 'increase from 297' statement)
  • Total revenue per HIC $27,811, +6% YoY
  • New metrics introduced: total managed payments $1.786B and Payment Solutions revenue rate 2.3%
  • Fiscal 2027 guidance unchanged: revenue $510M-$520M; adjusted EBITDA $125M-$135M

AI IconCapital Funding

  • March 13 refinancing: repaid bridge loan with $92M borrowings from new 5-year $275M senior secured revolving credit facility with Capital One, maturing March 13, 2031
  • New facility usage: $84M borrowings outstanding at April 30, 2026; $8M paydown during the quarter
  • Cash: $76.4M cash/cash equivalents/restricted cash at April 30, 2026 vs $73.8M at Jan 31, 2026; $1.7M restricted cash included with long-term assets
  • Operating cash flow $23.9M; free cash flow $16.4M (both +$9.1M and +$8.9M YoY, respectively)
  • Access One securitization facility with PNC: limit increased to $300M (from $200M) and extended through April 2029

AI IconStrategy & Ops

  • Shift in monetization mix: subscription pricing moderated to support retention while downstream economics improve via Payments and Network Solutions
  • Implementation of restructuring plan in May 2026 (post-quarter): intended to reduce operating expenses and align cost structure; meaningful annualized run-rate savings reflected in FY27 adjusted EBITDA outlook
  • Ongoing automation/efficiency efforts highlighted, including adoption of artificial intelligence to reduce reliance on manual processes

AI IconMarket Outlook

  • FY2027 revenue guidance maintained at $510M-$520M (assumes ~$37M contribution from Access One and no additional revenue from potential future acquisitions completed between now and Jan 31, 2027)
  • FY2027 adjusted EBITDA guidance maintained at $125M-$135M
  • AHSC growth outlook maintained in the mid-single-digit percentage range
  • Total revenue per AHSC outlook maintained to grow in the low single-digit percentage range
  • Management commentary: Network Solutions clients committing lower spend levels in 2H FY27 than anticipated last December; more variability in internal Network Solutions revenue forecasting in 2H each fiscal year

AI IconRisks & Headwinds

  • Network Solutions second-half variability: clients committing lower spend levels due to brand-specific dynamics and regulatory policy impacts (not deemed structural demand shift)
  • Forecasting variability increasing for internal Network Solutions revenue models in 2H of each fiscal year
  • Provider/product success dependent on adoption and engagement; management emphasizes friction reduction via product design rather than creating new problems (implies execution risk)

Q&A: Analyst Interest

  • Access One securitization expansion: analysts asked for quantification of incremental opportunity (cross-selling and economics for non-investment-grade providers). Management emphasized milestone value for expanding addressable market, improving cash flow for providers, and noted economics could differ but was not quantified; more detail pointed to prepared materials and letter.
  • Network Solutions guidance embedded drivers (Provider Connect): analyst sought what is specifically included in FY27 guidance and asked for deeper detail on momentum. Management highlighted two threads: patient intake demand variability and newly launched Provider Connect (started from near zero in FY20), giving a runway for FY28-30 growth beyond Patient Connect.
  • Subscription moderation and sequential decline: analyst questioned why subscription declined 6% sequentially and whether subscription still expects low-single-digit growth later in FY27. Management said revenue-line outlooks are not disclosed; total revenue per AHSC is key and reflects strategy embedded in guidance. They reiterated that the $510M-$520M revenue outlook already captures this trajectory.

Sentiment: MIXED

Note: This summary was synthesized by AI from the PHR Q1 2027 (ended April 30, 2026) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for PHR.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (PHR)

© 2026 Stock Market Info — Phreesia, Inc. (PHR) Financial Profile